• 1. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 2. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 3. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 4. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 5. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?
  Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312

Tert-butyl 4-(3-chloroquinoxalin-2-yl)piperazine-1-carboxylate (CAS No. 651047-41-5)

Tert-butyl 4-(3-chloroquinoxalin-2-yl)piperazine-1-carboxylate (CAS No. 651047-41-5) is a versatile compound with significant potential in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique structure, which combines a tert-butyl carbamate group with a piperazine ring substituted by a 3-chloroquinoxaline moiety. The combination of these functional groups imparts distinct chemical and biological properties, making it an intriguing candidate for various applications.

The tert-butyl carbamate group is known for its ability to protect the amine functionality, which is crucial in synthetic pathways and can be selectively removed under mild conditions. This feature makes Tert-butyl 4-(3-chloroquinoxalin-2-yl)piperazine-1-carboxylate an excellent intermediate in the synthesis of complex molecules, particularly those with therapeutic potential. The piperazine ring is a common structural motif in many bioactive compounds, often contributing to the binding affinity and selectivity of drugs targeting specific receptors or enzymes.

The 3-chloroquinoxaline moiety adds further complexity and functionality to the molecule. Quinoxalines are heterocyclic compounds with a wide range of biological activities, including antimicrobial, antiviral, and anticancer properties. The presence of a chlorine atom at the 3-position can influence the electronic properties of the quinoxaline ring, potentially affecting its interactions with biological targets. This makes Tert-butyl 4-(3-chloroquinoxalin-2-yl)piperazine-1-carboxylate a valuable scaffold for the development of novel therapeutic agents.

Recent studies have highlighted the potential of Tert-butyl 4-(3-chloroquinoxalin-2-yl)piperazine-1-carboxylate in various areas of medicinal chemistry. For instance, researchers have explored its use as a building block in the synthesis of selective serotonin reuptake inhibitors (SSRIs), which are widely used to treat depression and anxiety disorders. The compound's ability to modulate serotonin levels through its interaction with serotonin transporters has been a focus of several preclinical studies.

In addition to its applications in central nervous system (CNS) disorders, Tert-butyl 4-(3-chloroquinoxalin-2-yl)piperazine-1-carboxylate has shown promise in cancer research. Studies have demonstrated that derivatives of this compound can exhibit potent antiproliferative activity against various cancer cell lines. The mechanism of action involves the inhibition of key signaling pathways involved in cell growth and survival, such as the PI3K/AKT and MAPK pathways. These findings suggest that Tert-butyl 4-(3-chloroquinoxalin-2-yl)piperazine-1-carboxylate could serve as a lead compound for the development of novel anticancer drugs.

The synthetic accessibility of Tert-butyl 4-(3-chloroquinoxalin-2-yl)piperazine-1-carboxylate is another factor contributing to its appeal in pharmaceutical research. Various synthetic routes have been developed to efficiently prepare this compound, allowing for large-scale production if needed. One common approach involves the reaction of tert-butyl piperazine-1-carboxylate with 2-chloroquinazoline or related precursors under suitable conditions. The versatility of these synthetic methods enables chemists to introduce additional functional groups or modifications to tailor the properties of the final product.

From a pharmacological perspective, Tert-butyl 4-(3-chloroquinoxalin-2-yl)piperazine-1-carboxylate has been evaluated for its safety and efficacy in preclinical models. Animal studies have shown that it exhibits favorable pharmacokinetic properties, including good oral bioavailability and low toxicity profiles. These characteristics are essential for advancing compounds into clinical trials and ultimately into therapeutic use.

In conclusion, Tert-butyl 4-(3-chloroquinoxalin-2-yl)piperazine-1-carboxylate (CAS No. 651047-41-5) is a promising compound with diverse applications in medicinal chemistry and pharmaceutical research. Its unique structural features and biological activities make it an attractive candidate for further investigation and development as a therapeutic agent. Ongoing research continues to uncover new insights into its potential uses, underscoring its significance in the field.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)